메뉴 건너뛰기




Volumn 9, Issue 3, 2005, Pages 453-471

Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; COLCHICINE; CONSENSUS INTERFERON; CPG 10101; IDN 1566; INTERFERON; ISIS 14803; JTC 003; MAXIMINE; MERIMEPODIB; PEGINTERFERON; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; UT 231B; VALOPICITABINE; VIRAMADINE; VIRUS RNA;

EID: 22044450048     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2005.05.002     Document Type: Review
Times cited : (15)

References (86)
  • 1
    • 0022868893 scopus 로고
    • Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon
    • J.H. Hoofnagle, K.D. Mullen, and B. Jones Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon N Engl J Med 315 1986 1575 1578
    • (1986) N Engl J Med , vol.315 , pp. 1575-1578
    • Hoofnagle, J.H.1    Mullen, K.D.2    Jones, B.3
  • 2
    • 0023137301 scopus 로고
    • Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy
    • B.J. Thomson, M. Doran, and A.M.L. Lever Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy Lancet 1 1987 539 541
    • (1987) Lancet , vol.1 , pp. 539-541
    • Thomson, B.J.1    Doran, M.2    Lever, A.M.L.3
  • 3
    • 0029054011 scopus 로고
    • A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis
    • T. Poynard, P. Bedossa, and M. Chevallier A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis N Engl J Med 332 1995 1457 1462
    • (1995) N Engl J Med , vol.332 , pp. 1457-1462
    • Poynard, T.1    Bedossa, P.2    Chevallier, M.3
  • 4
    • 0032547938 scopus 로고    scopus 로고
    • Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
    • J.G. McHutchinson, S. Gordon, and E.R. Schiff Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1998 1485 1492
    • (1998) N Engl J Med , vol.339 , pp. 1485-1492
    • McHutchinson, J.G.1    Gordon, S.2    Schiff, E.R.3
  • 5
    • 0032585237 scopus 로고    scopus 로고
    • Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
    • T. Poynard, P. Marcellin, and S.S. Lee Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1998 1426 1432
    • (1998) Lancet , vol.352 , pp. 1426-1432
    • Poynard, T.1    Marcellin, P.2    Lee, S.S.3
  • 6
    • 17744389383 scopus 로고    scopus 로고
    • Efficacy and safety of pegylated (40-KD) interferon α-2a compared with interferon α-2a in non-cirrhotic patients with chronic hepatitis C
    • K.R. Reddy, T.L. Wright, and P.J. Pockros Efficacy and safety of pegylated (40-KD) interferon α-2a compared with interferon α-2a in non-cirrhotic patients with chronic hepatitis C Hepatology 33 2001 433 438
    • (2001) Hepatology , vol.33 , pp. 433-438
    • Reddy, K.R.1    Wright, T.L.2    Pockros, P.J.3
  • 7
    • 0034619946 scopus 로고    scopus 로고
    • Peginterferon-alfa-2a in patients with chronic hepatitis C
    • S. Zeuzem, S.V. Feinman, and J. Rasenack Peginterferon-alfa-2a in patients with chronic hepatitis C N Engl J Med 343 2000 1666 1672
    • (2000) N Engl J Med , vol.343 , pp. 1666-1672
    • Zeuzem, S.1    Feinman, S.V.2    Rasenack, J.3
  • 8
    • 0034619980 scopus 로고    scopus 로고
    • Peginterferon Alfa-2a in patients with chronic hepatitis C and cirrhosis
    • E.J. Heathcote, M.L. Shiffman, and W.G. Cooksley Peginterferon Alfa-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med 343 2000 1673 1680
    • (2000) N Engl J Med , vol.343 , pp. 1673-1680
    • Heathcote, E.J.1    Shiffman, M.L.2    Cooksley, W.G.3
  • 9
    • 17844403232 scopus 로고    scopus 로고
    • A randomized, double-blind trial comparing peginterferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
    • K.L. Lindsay, C. Trepo, and T. Heintges A randomized, double-blind trial comparing peginterferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology 34 2001 395 403
    • (2001) Hepatology , vol.34 , pp. 395-403
    • Lindsay, K.L.1    Trepo, C.2    Heintges, T.3
  • 10
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial
    • M.P. Manns, J.G. McHutchinson, and S.C. Gordon Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 2001 958 965
    • (2001) Lancet , vol.358 , pp. 958-965
    • Manns, M.P.1    McHutchinson, J.G.2    Gordon, S.C.3
  • 11
    • 0037179698 scopus 로고    scopus 로고
    • Combination of peginterferon alfa-2a (40 kd) plus ribavirin in patients with chronic hepatitis C virus infection
    • M.W. Fried, M.L. Shiffman, and K.R. Reddy Combination of peginterferon alfa-2a (40 kd) plus ribavirin in patients with chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
    • (2002) N Engl J Med , vol.347 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 12
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
    • S.J. Hadziyannis, H. Sette Jr, and T.R. Morgan Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
    • (2004) Ann Intern Med , vol.140 , pp. 346-355
    • Hadziyannis, S.J.1    Sette Jr., H.2    Morgan, T.R.3
  • 13
    • 11144358311 scopus 로고    scopus 로고
    • Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
    • M.L. Shiffman, A.M. Di Bisceglie, and K.L. Lindsay Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment Gastroenterology 126 2004 1015 1023
    • (2004) Gastroenterology , vol.126 , pp. 1015-1023
    • Shiffman, M.L.1    Di Bisceglie, A.M.2    Lindsay, K.L.3
  • 14
    • 0242708367 scopus 로고    scopus 로고
    • Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: Final results
    • I.M. Jacobsen, F. Ahmed, and M.W. Russo Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: final results Gastroenterology 124 Suppl 1 2003 A-714
    • (2003) Gastroenterology , vol.124 , Issue.SUPPL. 1 , pp. 714
    • Jacobsen, I.M.1    Ahmed, F.2    Russo, M.W.3
  • 15
    • 0242638517 scopus 로고    scopus 로고
    • Efficacy and safety of peginterferon alfa-2a combination therapies in patients who relapsed on rebetron therapy
    • S.K. Herrine, R. Brown Jr, and S. Esposito Efficacy and safety of peginterferon alfa-2a combination therapies in patients who relapsed on rebetron therapy Hepatology 36 Suppl 1 2002 358A
    • (2002) Hepatology , vol.36 , Issue.SUPPL. 1
    • Herrine, S.K.1    Brown Jr., R.2    Esposito, S.3
  • 16
    • 2442554763 scopus 로고    scopus 로고
    • Efficacy of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C previously unresponsive to interferon-based therapy
    • E.L. Krawitt, S.D. Lidofsky, and N. Ferrentino Efficacy of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C previously unresponsive to interferon-based therapy Hepatology 36 Suppl 1 2002 359A
    • (2002) Hepatology , vol.36 , Issue.SUPPL. 1
    • Krawitt, E.L.1    Lidofsky, S.D.2    Ferrentino, N.3
  • 17
    • 2442626359 scopus 로고    scopus 로고
    • Use of diagnostic testing for managing hepatitis C virus infection
    • A. Ferreira-Gonzalez, and M.L. Shiffman Use of diagnostic testing for managing hepatitis C virus infection Semin Liver Dis 24 Suppl 2 2004 9 18
    • (2004) Semin Liver Dis , vol.24 , Issue.SUPPL. 2 , pp. 9-18
    • Ferreira-Gonzalez, A.1    Shiffman, M.L.2
  • 18
    • 0030928696 scopus 로고    scopus 로고
    • Therapy of hepatitis C: Overview
    • K.L. Lindsay Therapy of hepatitis C: overview Hepatology 27 Suppl 1 1997 71S 77S
    • (1997) Hepatology , vol.27 , Issue.SUPPL. 1
    • Lindsay, K.L.1
  • 19
    • 0036829985 scopus 로고    scopus 로고
    • Introduction to therapy of hepatitis C
    • K.L. Lindsay Introduction to therapy of hepatitis C Hepatology 36 Suppl 1 2002 S114 S120
    • (2002) Hepatology , vol.36 , Issue.SUPPL. 1
    • Lindsay, K.L.1
  • 20
    • 0041822106 scopus 로고    scopus 로고
    • Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    • G.L. Davis, J.B. Wong, and J.G. McHutchison Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 652
    • (2003) Hepatology , vol.38 , pp. 645-652
    • Davis, G.L.1    Wong, J.B.2    McHutchison, J.G.3
  • 21
    • 0032954992 scopus 로고    scopus 로고
    • Establishment of the first international standard for nucleic acid amplification technology assays for HCV RNA. WHO collaborative study group
    • J. Saldanha, N. Lelie, and A. Heath Establishment of the first international standard for nucleic acid amplification technology assays for HCV RNA. WHO collaborative study group Vox Sang 76 1999 149 158
    • (1999) Vox Sang , vol.76 , pp. 149-158
    • Saldanha, J.1    Lelie, N.2    Heath, A.3
  • 22
    • 0038408809 scopus 로고    scopus 로고
    • Comparison of three commercially available assays for HCV RNA using the international unit standard: Implications for management of patients with chronic hepatitis C virus infection in clinical practice
    • M.L. Shiffman, A. Ferreira-Gonzalez, and K.R. Reddy Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice Am J Gastroenterol 98 2003 1159 1166
    • (2003) Am J Gastroenterol , vol.98 , pp. 1159-1166
    • Shiffman, M.L.1    Ferreira-Gonzalez, A.2    Reddy, K.R.3
  • 23
    • 0042090454 scopus 로고    scopus 로고
    • Comparison of different HCV viral load and genotyping assays
    • J.C. Anderson, J. Simonetti, and D.G. Fisher Comparison of different HCV viral load and genotyping assays J Clin Virol 28 2003 27 37
    • (2003) J Clin Virol , vol.28 , pp. 27-37
    • Anderson, J.C.1    Simonetti, J.2    Fisher, D.G.3
  • 24
    • 0034764239 scopus 로고    scopus 로고
    • Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests
    • F.S. Nolte, M.W. Fried, and M.L. Shiffman Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests J Clin Microbiol 39 2001 4005 4012
    • (2001) J Clin Microbiol , vol.39 , pp. 4005-4012
    • Nolte, F.S.1    Fried, M.W.2    Shiffman, M.L.3
  • 25
    • 0033224502 scopus 로고    scopus 로고
    • Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy
    • C. Morishima, and D.R. Gretch Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy Clin Liver Dis 3 1999 717 740
    • (1999) Clin Liver Dis , vol.3 , pp. 717-740
    • Morishima, C.1    Gretch, D.R.2
  • 26
    • 0036830567 scopus 로고    scopus 로고
    • Monitoring of viral levels during therapy of hepatitis C
    • G.L. Davis Monitoring of viral levels during therapy of hepatitis C Hepatology 36 Suppl 1 2002 S145 S151
    • (2002) Hepatology , vol.36 , Issue.SUPPL. 1
    • Davis, G.L.1
  • 27
    • 6944241734 scopus 로고    scopus 로고
    • Side effects of medical therapy for chronic hepatitis C
    • M.L. Shiffman Side effects of medical therapy for chronic hepatitis C Ann Hepatol 3 2004 5 10
    • (2004) Ann Hepatol , vol.3 , pp. 5-10
    • Shiffman, M.L.1
  • 28
    • 0036788338 scopus 로고    scopus 로고
    • Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
    • J.G. McHutchison, M. Manns, and K. Patel Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
    • (2002) Gastroenterology , vol.123 , pp. 1061-1069
    • McHutchison, J.G.1    Manns, M.2    Patel, K.3
  • 29
    • 0001474935 scopus 로고    scopus 로고
    • Peginterferon alfa-2a in combination with ribavirin: Efficacy and safety results from a phase III randomized, double-blind, multicenter trial examining effect of duration of treatment and ribavirin dose
    • S. Hadziyannis, H. Cheinquer, and T. Morgan Peginterferon alfa-2a in combination with ribavirin: efficacy and safety results from a phase III randomized, double-blind, multicenter trial examining effect of duration of treatment and ribavirin dose J Hepatol 36 Supp 1 2002 3
    • (2002) J Hepatol , vol.36 , Issue.SUPPL. 1 , pp. 3
    • Hadziyannis, S.1    Cheinquer, H.2    Morgan, T.3
  • 30
    • 22044448801 scopus 로고    scopus 로고
    • The impact of peginterferon and ribavirin dosing on sustained virologic response in patients with chronic hepatitis C virus undergoing retreatment in the HALT-C trial. HALT-C trial group
    • M.L. Shiffman, T.R. Morgan, and M.G. Ghany The impact of peginterferon and ribavirin dosing on sustained virologic response in patients with chronic hepatitis C virus undergoing retreatment in the HALT-C trial. HALT-C trial group Hepatology 40 Suppl 1 2004 314A
    • (2004) Hepatology , vol.40 , Issue.SUPPL. 1
    • Shiffman, M.L.1    Morgan, T.R.2    Ghany, M.G.3
  • 31
    • 17544367057 scopus 로고    scopus 로고
    • Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage
    • L. De Franceschi, G. Fattovich, and F. Turrini Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage Hepatology 31 2000 997 1004
    • (2000) Hepatology , vol.31 , pp. 997-1004
    • De Franceschi, L.1    Fattovich, G.2    Turrini, F.3
  • 32
    • 0035882198 scopus 로고    scopus 로고
    • A randomized, controlled trial to determine if continuing ribavirin as monotherapy in patients who responded to interferon/ribavirin combination therapy will enhance sustained virologic response
    • M.L. Shiffman, C.M. Hofmann, and R.K. Sterling A randomized, controlled trial to determine if continuing ribavirin as monotherapy in patients who responded to interferon/ribavirin combination therapy will enhance sustained virologic response J Infect Dis 184 2001 405 409
    • (2001) J Infect Dis , vol.184 , pp. 405-409
    • Shiffman, M.L.1    Hofmann, C.M.2    Sterling, R.K.3
  • 33
    • 0032895782 scopus 로고    scopus 로고
    • Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients
    • W.C. Maddrey Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients Semin Liver Dis 19 Suppl 1 1999 67 75
    • (1999) Semin Liver Dis , vol.19 , Issue.SUPPL. 1 , pp. 67-75
    • Maddrey, W.C.1
  • 34
    • 2442626358 scopus 로고    scopus 로고
    • Reasons for discontinuation of treatment of chronic hepatitis C: An interim analysis of the Frontier trial
    • M. Nichols, and M. Kugelmas Reasons for discontinuation of treatment of chronic hepatitis C: an interim analysis of the Frontier trial Gastroenterology 124 Suppl 1 2003 A703
    • (2003) Gastroenterology , vol.124 , Issue.SUPPL. 1 , pp. 703
    • Nichols, M.1    Kugelmas, M.2
  • 35
    • 0242437747 scopus 로고    scopus 로고
    • Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa
    • D.T. Dieterich, R. Wasserman, and N. Brau Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa Am J Gastroenterol 98 2003 2491 2499
    • (2003) Am J Gastroenterol , vol.98 , pp. 2491-2499
    • Dieterich, D.T.1    Wasserman, R.2    Brau, N.3
  • 36
    • 11144358403 scopus 로고    scopus 로고
    • Correction of anemia with epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind study
    • N.H. Afdhal, D.T. Dieterich, and P.J. Pockros Correction of anemia with epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind study Gastroenterology 126 2004 1302 1311
    • (2004) Gastroenterology , vol.126 , pp. 1302-1311
    • Afdhal, N.H.1    Dieterich, D.T.2    Pockros, P.J.3
  • 37
    • 10644237092 scopus 로고    scopus 로고
    • Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy
    • P.J. Pockros, M.L. Shiffman, and E.R. Schiff Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy Hepatology 40 2004 1450 1458
    • (2004) Hepatology , vol.40 , pp. 1450-1458
    • Pockros, P.J.1    Shiffman, M.L.2    Schiff, E.R.3
  • 38
  • 39
    • 0022655605 scopus 로고
    • Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage
    • A.L. Boks, E.J. Brommer, and S.W. Schalm Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage Hepatology 6 1986 79 86
    • (1986) Hepatology , vol.6 , pp. 79-86
    • Boks, A.L.1    Brommer, E.J.2    Schalm, S.W.3
  • 40
    • 1842765642 scopus 로고    scopus 로고
    • Neuropsychiatric side effects of HCV therapy and their treatment focus on IFN alpha-induced depression
    • P. Hauser Neuropsychiatric side effects of HCV therapy and their treatment focus on IFN alpha-induced depression Gastroenterol Clin North Am 33 Suppl 1 2004 S35 S50
    • (2004) Gastroenterol Clin North Am , vol.33 , Issue.SUPPL. 1
    • Hauser, P.1
  • 41
    • 2442425456 scopus 로고    scopus 로고
    • Psychopharmacologic treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: A prospective case series and a discussion of biologic mechanisms
    • C. Maddock, A. Baita, and M.G. Orru Psychopharmacologic treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biologic mechanisms J Psychopharmacol 18 2004 41 46
    • (2004) J Psychopharmacol , vol.18 , pp. 41-46
    • Maddock, C.1    Baita, A.2    Orru, M.G.3
  • 44
    • 0033945197 scopus 로고    scopus 로고
    • Drinking habits of subjects with hepatitis C virus-related chronic liver disease: Prevalence and effect on clinical, virological and pathological aspects
    • C. Loguercio, M. Di Pierro, and M.P. Di Marino Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects Alcohol 35 2000 296 301
    • (2000) Alcohol , vol.35 , pp. 296-301
    • Loguercio, C.1    Di Pierro, M.2    Di Marino, M.P.3
  • 45
    • 0036829486 scopus 로고    scopus 로고
    • Prevention and treatment of hepatitis C in injection drug users
    • B.R. Edlin Prevention and treatment of hepatitis C in injection drug users Hepatology 36 Suppl 1 2002 S210 S219
    • (2002) Hepatology , vol.36 , Issue.SUPPL. 1
    • Edlin, B.R.1
  • 46
    • 2442465564 scopus 로고    scopus 로고
    • The impact of negative prognostic factors on hepatitis C treatment outcomes in recovering injection drug users
    • D.L. Sylvestre, and B.J. Clements The impact of negative prognostic factors on hepatitis C treatment outcomes in recovering injection drug users Hepatology 36 2002 223A
    • (2002) Hepatology , vol.36
    • Sylvestre, D.L.1    Clements, B.J.2
  • 47
    • 0036830350 scopus 로고    scopus 로고
    • Future therapy of hepatitis C
    • J.G. McHutchison, and K. Patel Future therapy of hepatitis C Hepatology 36 2002 S245 S252
    • (2002) Hepatology , vol.36
    • McHutchison, J.G.1    Patel, K.2
  • 48
    • 0031945834 scopus 로고    scopus 로고
    • Re-treatment of chronic hepatitis C with consensus interferon
    • E.J. Heathcote, E.B. Keeffe, and S.S. Lee Re-treatment of chronic hepatitis C with consensus interferon Hepatology 27 1998 1136 1143
    • (1998) Hepatology , vol.27 , pp. 1136-1143
    • Heathcote, E.J.1    Keeffe, E.B.2    Lee, S.S.3
  • 49
    • 2442418677 scopus 로고    scopus 로고
    • Successful retreatment of peginterferon nonresponders with chronic hepatitis C with high dose consensus interferon induction therapy
    • S. Kaiser, H. Hass, and M. Gregor Successful retreatment of peginterferon nonresponders with chronic hepatitis C with high dose consensus interferon induction therapy Gastroenterology 124 Suppl 1 2003 A700
    • (2003) Gastroenterology , vol.124 , Issue.SUPPL. 1 , pp. 700
    • Kaiser, S.1    Hass, H.2    Gregor, M.3
  • 50
    • 15944407884 scopus 로고    scopus 로고
    • Comparison of African American and non-African American patient end of treatment response for PEGIFN alpha-2a and weight based ribavirin nonresponders retreated with IFN alfacon-1 and weight based ribavirin
    • C. Leevy II, C. Chamers, and L. Blatt Comparison of African American and non-African American patient end of treatment response for PEGIFN alpha-2a and weight based ribavirin nonresponders retreated with IFN alfacon-1 and weight based ribavirin Hepatology 40 Suppl 1 2004 240A
    • (2004) Hepatology , vol.40 , Issue.SUPPL. 1
    • Leevy II, C.1    Chamers, C.2    Blatt, L.3
  • 51
    • 2442665224 scopus 로고    scopus 로고
    • Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites
    • A.J. Muir, J.D. Bornstein, and P.G. Killenberg Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites N Engl J Med 350 2004 2265 2271
    • (2004) N Engl J Med , vol.350 , pp. 2265-2271
    • Muir, A.J.1    Bornstein, J.D.2    Killenberg, P.G.3
  • 52
    • 22044454893 scopus 로고    scopus 로고
    • Peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who failed to respond to interferon and ribavirin: Final results of the Spanish high dose induction pilot trial
    • M. Diago, J. Crespo, and A. Oliveira Peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who failed to respond to interferon and ribavirin: final results of the Spanish high dose induction pilot trial Hepatology 40 Suppl 1 2004 389A
    • (2004) Hepatology , vol.40 , Issue.SUPPL. 1
    • Diago, M.1    Crespo, J.2    Oliveira, A.3
  • 54
    • 0032898676 scopus 로고    scopus 로고
    • The roles of amantadine, rimantadine, ursodeoxycholic acid and NSAIDs, alone or in combination with alfa interferons in the treatment of chronic hepatitis C
    • Z.M. Younossi, and R.P. Perrillo The roles of amantadine, rimantadine, ursodeoxycholic acid and NSAIDs, alone or in combination with alfa interferons in the treatment of chronic hepatitis C Semin Liver Dis 19 1999 95 102
    • (1999) Semin Liver Dis , vol.19 , pp. 95-102
    • Younossi, Z.M.1    Perrillo, R.P.2
  • 55
    • 0030822539 scopus 로고    scopus 로고
    • Treatment of chronic hepatitis C with amantadine
    • J.P. Smith Treatment of chronic hepatitis C with amantadine Dig Dis Sci 42 1997 1681 1687
    • (1997) Dig Dis Sci , vol.42 , pp. 1681-1687
    • Smith, J.P.1
  • 56
    • 18244398956 scopus 로고    scopus 로고
    • Interferon and amantadine in naive chronic hepatitis C: A double-blind, randomized, placebo-controlled trial
    • B. Helbling, I. Stamenic, and F. Viani Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial Hepatology 35 2002 447 454
    • (2002) Hepatology , vol.35 , pp. 447-454
    • Helbling, B.1    Stamenic, I.2    Viani, F.3
  • 57
    • 12444260678 scopus 로고    scopus 로고
    • Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C
    • G. Teuber, M. Pascu, and T. Berg Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C J Hepatol 39 2003 606 613
    • (2003) J Hepatol , vol.39 , pp. 606-613
    • Teuber, G.1    Pascu, M.2    Berg, T.3
  • 58
    • 9144240563 scopus 로고    scopus 로고
    • Randomized, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naive patients with chronic hepatitis C
    • P.J. Thuluvath, A. Maheshwari, and J. Mehdi Randomized, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naive patients with chronic hepatitis C Gut 53 2004 130 135
    • (2004) Gut , vol.53 , pp. 130-135
    • Thuluvath, P.J.1    Maheshwari, A.2    Mehdi, J.3
  • 59
    • 10744224044 scopus 로고    scopus 로고
    • Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: Meta-analysis of individual patient data from six clinical trials
    • A. Mangia, G. Leandro, and B. Helbling Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials J Hepatol 40 2004 478 483
    • (2004) J Hepatol , vol.40 , pp. 478-483
    • Mangia, A.1    Leandro, G.2    Helbling, B.3
  • 60
    • 2442596862 scopus 로고    scopus 로고
    • End of treatment and sustained response to peginterferon alfa-2a plus ribavirin and amantadine and to induction therapy with interferon alfa-2a plus ribavirin and amantadine in interferon/ribavirin nonresponders with chronic hepatitis C
    • S. Fargion, M. Borzio, and O. Predabissi End of treatment and sustained response to peginterferon alfa-2a plus ribavirin and amantadine and to induction therapy with interferon alfa-2a plus ribavirin and amantadine in interferon/ribavirin nonresponders with chronic hepatitis C Hepatology 38 Suppl 1 2003 733A
    • (2003) Hepatology , vol.38 , Issue.SUPPL. 1
    • Fargion, S.1    Borzio, M.2    Predabissi, O.3
  • 61
    • 4444276637 scopus 로고    scopus 로고
    • Triple therapy compared to standard pegylated interferon alfa-2b and weight based ribavirin for previous nonresponders and relapsers with chronic hepatitis C
    • N.S. Cantu, M. Davis, and N. Afdahl Triple therapy compared to standard pegylated interferon alfa-2b and weight based ribavirin for previous nonresponders and relapsers with chronic hepatitis C Hepatology 38 Suppl 1 2003 742A
    • (2003) Hepatology , vol.38 , Issue.SUPPL. 1
    • Cantu, N.S.1    Davis, M.2    Afdahl, N.3
  • 62
    • 12644299637 scopus 로고    scopus 로고
    • Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C
    • M.L. Shiffman, C.M. Hofmann, and E.B. Thompson Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C Hepatology 26 1997 780 785
    • (1997) Hepatology , vol.26 , pp. 780-785
    • Shiffman, M.L.1    Hofmann, C.M.2    Thompson, E.B.3
  • 63
    • 0033015325 scopus 로고    scopus 로고
    • Histologic improvement in response to interferon therapy in chronic hepatitis C
    • M.L. Shiffman Histologic improvement in response to interferon therapy in chronic hepatitis C Viral Hepatitis Rev 5 1999 27 43
    • (1999) Viral Hepatitis Rev , vol.5 , pp. 27-43
    • Shiffman, M.L.1
  • 64
    • 0036242165 scopus 로고    scopus 로고
    • Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
    • T. Poynard, J. McHutchison, and M. Manns Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
    • (2002) Gastroenterology , vol.122 , pp. 1303-1313
    • Poynard, T.1    McHutchison, J.2    Manns, M.3
  • 65
    • 0343111507 scopus 로고    scopus 로고
    • Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C
    • Y. Imai, S. Kawata, and S. Tamura Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C Ann Intern Med 129 1998 94 99
    • (1998) Ann Intern Med , vol.129 , pp. 94-99
    • Imai, Y.1    Kawata, S.2    Tamura, S.3
  • 66
    • 0036320660 scopus 로고    scopus 로고
    • Interferon therapy prolonged life expectancy among chronic hepatitis C patients
    • H. Yoshida, Y. Arakawa, and M. Sata Interferon therapy prolonged life expectancy among chronic hepatitis C patients Gastroenterology 123 2002 483 491
    • (2002) Gastroenterology , vol.123 , pp. 483-491
    • Yoshida, H.1    Arakawa, Y.2    Sata, M.3
  • 67
    • 0030744373 scopus 로고
    • Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European concerted action on viral hepatitis
    • G. Fattovich, G. Giustina, and F. Degos Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European concerted action on viral hepatitis J Hepatol 27 1977 201 205
    • (1977) J Hepatol , vol.27 , pp. 201-205
    • Fattovich, G.1    Giustina, G.2    Degos, F.3
  • 68
    • 0032736213 scopus 로고    scopus 로고
    • A randomized, controlled trial of maintenance interferon for treatment of chronic hepatitis C non-responders
    • M.L. Shiffman, C.M. Hofmann, and M.J. Contos A randomized, controlled trial of maintenance interferon for treatment of chronic hepatitis C non-responders Gastroenterology 117 1999 1164 1172
    • (1999) Gastroenterology , vol.117 , pp. 1164-1172
    • Shiffman, M.L.1    Hofmann, C.M.2    Contos, M.J.3
  • 69
    • 15844431546 scopus 로고    scopus 로고
    • The long term pathological evolution of chronic hepatitis C
    • M. Yano, H. Kumada, and M. Kage The long term pathological evolution of chronic hepatitis C Hepatology 23 1996 1334 1340
    • (1996) Hepatology , vol.23 , pp. 1334-1340
    • Yano, M.1    Kumada, H.2    Kage, M.3
  • 70
    • 0037219481 scopus 로고    scopus 로고
    • Progression of fibrosis in chronic hepatitis C
    • M.G. Ghany, D.E. Kleiner, and H. Alter Progression of fibrosis in chronic hepatitis C Gastroenterology 124 2003 97 104
    • (2003) Gastroenterology , vol.124 , pp. 97-104
    • Ghany, M.G.1    Kleiner, D.E.2    Alter, H.3
  • 71
    • 4644286380 scopus 로고    scopus 로고
    • Evolution of the HALT-C trial: Pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders
    • W.M. Lee, J.L. Dienstag, and K.L. Lindsay Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders Control Clin Trials 25 2004 472 492
    • (2004) Control Clin Trials , vol.25 , pp. 472-492
    • Lee, W.M.1    Dienstag, J.L.2    Lindsay, K.L.3
  • 72
    • 14844316890 scopus 로고    scopus 로고
    • Colchicine versus Peg-Intron long term (CoPilot) trial: Interm analysis of clinical outcomes at year 2
    • N. Afdhal, B. Freilich, and R. Levine Colchicine versus Peg-Intron long term (CoPilot) trial: interm analysis of clinical outcomes at year 2 Hepatology 40 Suppl 1 2004 239A
    • (2004) Hepatology , vol.40 , Issue.SUPPL. 1
    • Afdhal, N.1    Freilich, B.2    Levine, R.3
  • 73
    • 0038122772 scopus 로고    scopus 로고
    • Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin
    • J.H. Hoofnagle, M.G. Ghany, and D.E. Kleiner Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin Hepatology 38 2003 66 74
    • (2003) Hepatology , vol.38 , pp. 66-74
    • Hoofnagle, J.H.1    Ghany, M.G.2    Kleiner, D.E.3
  • 74
    • 0028825313 scopus 로고
    • Ribavirin as therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial
    • A.M. Di Bisceglie, H.S. Conjeevaram, and M.W. Fried Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial Ann Intern Med 123 1995 897 903
    • (1995) Ann Intern Med , vol.123 , pp. 897-903
    • Di Bisceglie, A.M.1    Conjeevaram, H.S.2    Fried, M.W.3
  • 75
    • 0030933395 scopus 로고    scopus 로고
    • Natural history of liver fibrosis progression in patients with chronic hepatitis C. the OBSVIRC, METAVIR, CLINVIR and DOSVIRC groups
    • T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINVIR and DOSVIRC groups Lancet 349 1997 825 832
    • (1997) Lancet , vol.349 , pp. 825-832
    • Poynard, T.1    Bedossa, P.2    Opolon, P.3
  • 76
    • 4444365401 scopus 로고    scopus 로고
    • The natural history of hepatitis C
    • N.H. Afdhal The natural history of hepatitis C Semin Liver Dis 24 Suppl 2 2004 3 8
    • (2004) Semin Liver Dis , vol.24 , Issue.SUPPL. 2 , pp. 3-8
    • Afdhal, N.H.1
  • 77
  • 78
    • 0031721879 scopus 로고    scopus 로고
    • Impact of alcohol on the histological and clinical progression of hepatitis C infection
    • T.E. Wiley, M. McCarthy, and L. Breidi Impact of alcohol on the histological and clinical progression of hepatitis C infection Hepatology 28 1998 805 809
    • (1998) Hepatology , vol.28 , pp. 805-809
    • Wiley, T.E.1    McCarthy, M.2    Breidi, L.3
  • 79
    • 11144225924 scopus 로고    scopus 로고
    • Hepatitis C and nonalcoholic fatty liver disease
    • S. Ramesh, and A.J. Sanyal Hepatitis C and nonalcoholic fatty liver disease Semin Liver Dis 24 2004 399 413
    • (2004) Semin Liver Dis , vol.24 , pp. 399-413
    • Ramesh, S.1    Sanyal, A.J.2
  • 80
    • 4143076848 scopus 로고    scopus 로고
    • Obesity and non-alcoholic fatty liver disease in chronic hepatitis C
    • Z.M. Younossi, A.J. McCullough, and J.P. Ong Obesity and non-alcoholic fatty liver disease in chronic hepatitis C J Clin Gastroenterol 38 2004 705 709
    • (2004) J Clin Gastroenterol , vol.38 , pp. 705-709
    • Younossi, Z.M.1    McCullough, A.J.2    Ong, J.P.3
  • 81
    • 4344629376 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver disease in individuals with severe obesity
    • P. Haynes, S. Liangpunsakul, and N. Chalasani Nonalcoholic fatty liver disease in individuals with severe obesity Clin Liver Dis 8 2004 535 547
    • (2004) Clin Liver Dis , vol.8 , pp. 535-547
    • Haynes, P.1    Liangpunsakul, S.2    Chalasani, N.3
  • 82
    • 0842300373 scopus 로고    scopus 로고
    • Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease
    • A. Lonardo, L.E. Adinolfi, and P. Loria Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease Gastroenterol 126 2004 586 597
    • (2004) Gastroenterol , vol.126 , pp. 586-597
    • Lonardo, A.1    Adinolfi, L.E.2    Loria, P.3
  • 83
    • 1942438217 scopus 로고    scopus 로고
    • Review article: Hepatitis vaccination in patients with chronic liver disease
    • G. Reiss, and E.B. Keeffe Review article: hepatitis vaccination in patients with chronic liver disease Aliment Pharmacol Ther 19 2004 715 727
    • (2004) Aliment Pharmacol Ther , vol.19 , pp. 715-727
    • Reiss, G.1    Keeffe, E.B.2
  • 84
    • 1842479859 scopus 로고    scopus 로고
    • Diagnosis, management, and treatment of hepatitis C
    • D.B. Strader, T. Wright, and D.L. Thomas Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171
    • (2004) Hepatology , vol.39 , pp. 1147-1171
    • Strader, D.B.1    Wright, T.2    Thomas, D.L.3
  • 85
    • 0032576759 scopus 로고    scopus 로고
    • Fulminant hepatitis associated with hepatitis a virus superinfection in patients with chronic hepatitis C
    • S. Vento, T. Garofano, and C. Renzini Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C N Engl J Med 338 1998 286 290
    • (1998) N Engl J Med , vol.338 , pp. 286-290
    • Vento, S.1    Garofano, T.2    Renzini, C.3
  • 86
    • 4444381836 scopus 로고    scopus 로고
    • Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection
    • R.K. Sterling, and M.S. Sulkowski Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection Semin Liver Dis 24 Suppl 2 2004 61 68
    • (2004) Semin Liver Dis , vol.24 , Issue.SUPPL. 2 , pp. 61-68
    • Sterling, R.K.1    Sulkowski, M.S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.